Braveheart Investment Group plc Investment update -- Kirkstall Limited (7748L)
08 Setembro 2023 - 3:00AM
UK Regulatory
TIDMBRH
RNS Number : 7748L
Braveheart Investment Group plc
08 September 2023
8 September 2023
Braveheart Investment Group plc
("Braveheart" or the "Group")
Investment update - Kirkstall Limited
Braveheart Investment Group (AIM: BRH), announces an update on
Kirkstall Limited ("Kirkstall" or the "Company"), a company within
the Group's investment portfolio.
Kirkstall, in conjunction with the Biomedical Ultrasonics,
Biotherapy and Biopharmaceutical Laboratory within the Institute of
Biomedical Engineering at the University of Oxford , has developed
an "organ on a chip" model of an innovative, milli-fluidic system,
human blood-brain barrier which has been used to map the
interaction between the blood-brain barrier and brain cancer.
This is the first time a dynamic milli-fluidic model has been
developed where the interactions between the blood-brain barrier
and medulloblastoma brain cancer spheroids have been demonstrated.
The model uses the Kirkstall's Quasi Vivo(R) platform, a unique
milli-fluidic system. This innovation will enable the observation
of the in vitro performance of drugs designed for treating brain
cancer and central nervous system diseases such as Alzheimer's.
Braveheart holds a 86.11% equity interest in Kirkstall. In
addition, it has provided unsecured interest free loans to
Kirkstall totalling GBP10,752 as at 31 March 2023.
Trevor Brown, CEO of Braveheart Investment Group plc, commented:
"It is exciting to observe how collaboration between Kirkstall and
Oxford University has resulted in an innovative and important
application for the Quasi Vivo platform."
For further information:
Braveheart Investment Group plc Tel: 01738
587555
Trevor Brown CEO
Allenby Capital Limited (Nominated Tel: 020
Adviser and Joint Broker) 3328 5656
James Reeve / George Payne
Peterhouse Capital Limited (Joint Tel: 020
Broker) 7469 0936
Duncan Vasey / Lucy Williams
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
PFUGZGGLVNLGFZM
(END) Dow Jones Newswires
September 08, 2023 02:00 ET (06:00 GMT)
Braveheart Investment (LSE:BRH)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Braveheart Investment (LSE:BRH)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024